Novartis Ag (NVS)
$90.04
0.53 (0.59%)
NVS Stock Quote Delayed 15 Minutes
Previous Close
$90.04
Market Cap
209.87B
PE Ratio
26.40
EPS
3.41
Volume (Avg. Vol.)
1.16M
Day's Range
89.37 - 90.22
52-Week Range
74.97 - 96.31
Dividend & Yield
2.98 (3.31%)
NVS Stock Predictions, Articles, and Novartis Ag News
3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
10 Smart Dividend Stocks for the Rest of the Year
Ford, Verizon and AbbVie are just a trio of the top dividend stocks to buy for the remainder of 2019, particularly if the broad market hits turbulence.
New Sanofi CEO 2019: 8 Things to Know About Paul Hudson
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.
Continued Smart M&A Moves Will Help Canopy Stock Break Out
Of course, the medical opportunity is massive, but Tilray competitor, Canopy Growth (NYSE:CGC), has been aggressively pursuing a multi-pronged approach that inherently diversifies the future revenue streams. CGC’s vision for THC as an ingredient in an array of consumer products separates them from an increasingly crowded industry.
4 Top Stock Trades for Tuesday: ROKU, ADSK, SPLK, NVS
Roku, Autodesk, Splunk and Novartis are our top stock trades on Friday. Going into the long weekend, see why we picked them for next week.
How and Why Tilray Stock Is a Buy Here
Following a long, steep correction and on the heels of earnings, there’s less to fear in stepping into a contrarian position in Tilray stock.
Don’t Let the Great Q1 Numbers Fool You into Buying Tilray Stock
After a revenue beat Tilray Inc (NASDAQ:TLRY) saw its stock jump 5 percent for the day. However, that optimism has faded rather quickly, and TLRY stock has not been able to capitalize on that momentum.
Here’s the Real Problem with Altria Overpaying for CRON Stock
Altria Group Inc (NYSE:MO) was the latest in a frenzied string of M&A and partnerships in the cannabis sector. Marijuana stocks have been the target of billion-dollar investments, and the $102 billion market cap company and owner of veteran cigarette brands Marlboro, Parliament, and Virginia Slims, last month that it was investing approximately $1.8 billion in Canadian-based Cronos Group Inc (NASDAQ:CRON), which is listed both on the TSX as well as the NASDAQ.
3 Big Stock Charts for Wednesday: Incyte, FMC and LyondellBasell
The stock charts of INCY, LYB and FMC are going to start this week's hump-day at a precipice. Here are the numbers to know.
Novartis News: NVS Stock Sinks Following Alcon Spin-Off
Novartis news about the company's spin-off of Alcon into its own publicly-traded company has NVS stock falling hard on Tuesday.
The Roche Merger Will Do Wonders for Spark Stock
As Spark Therapeutics gets acquired, existing shareholders, and Roche investors, will need to eveluate the merits of the deal.
Is Tilray Stock a Must-Buy Following New Partnership?
Tilray stock is still very expensive, even after its partnership with Novartis' Sandoz. However, TLRY is in a very tradable range.
Novartis Layoffs 2018: NVS to Cut 2,000 + Jobs
Novartis (NVS) announced that it was laying off 2,000 workers in 2018 as part of a global restructuring, according to a Tuesday announcement.
Novartis Stock Pops on Alcon Spinoff News
Novartis (NVS) stock got a boost today after the company announced plans to spin off its Alcon business sometime next year.
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
Novartis AG (ADR) Stock Drops on Q1 Earnings Miss
Novartis (NVS) stock took a hit on Thursday following the release of its earnings report for the first quarter of the year.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
